In adults with overweight or obesity receiving tirzepatide for weight loss, adding apitegromab does not change the amount of fat lost, visceral fat reduction, or cardiometabolic markers, but it preserves lean mass.
See the scientific wording
Apitegromab does not significantly alter fat mass loss, visceral fat, or cardiometabolic markers during tirzepatide-induced weight loss in adults with overweight or obesity over 24 weeks, and its effect is specific to lean mass preservation.
Very strong evidence
Randomized trialsOne high-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman2026
Apitegromab helps keep your muscles from shrinking when you lose weight with tirzepatide, but it doesn’t change how much fat you lose or affect your blood sugar or cholesterol levels.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
A drug blocks a natural brake on muscle growth, so when the body loses weight, muscles don't shrink as much. The drug stops a protein from becoming active, which lets muscle cells build more protein and break down less, keeping muscle mass stable even when fat is being lost.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In adults with overweight or obesity receiving tirzepatide for weight loss, adding apitegromab does not change the amount of fat lost, visceral fat reduction, or cardiometabolic markers, but it preserves lean mass.
Mechanism
1 studyThe drug blocks a natural signal that limits muscle growth, so muscles keep their mass during weight loss. It does not affect how the body burns fat or regulates blood sugar, because it only works on muscle tissue.
A drug blocks a natural brake on muscle growth, so when the body loses weight, muscles don't shrink as much. The drug stops a protein from becoming active, which lets muscle cells build more protein and break down less, keeping muscle mass stable even when fat is being lost.
A monoclonal antibody binds to inactive precursors of myostatin in the bloodstream, preventing their conversion into the active form
Inhibition of active myostatin removes suppression of satellite cell activation and muscle protein synthesis
Reduced myostatin signaling decreases ubiquitin-proteasome-mediated degradation of muscle proteins
The net increase in muscle protein accumulation counteracts catabolic signals induced by weight-loss therapies, preserving lean mass without affecting fat metabolism
Evidence from Studies
Supporting (1)
Community contributions welcome
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
Apitegromab helps keep your muscles from shrinking when you lose weight with tirzepatide, but it doesn’t change how much fat you lose or affect your blood sugar or cholesterol levels.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Apitegromab Combined with Tirzepatide on Body Composition and Cardiometabolic Outcomes in Obesity
Population: Adults with overweight or obesity receiving tirzepatide; Intervention: Addition of apitegromab; Comparator: Placebo plus tirzepatide; Outcomes: Changes in fat mass, visceral fat, and cardiometabolic markers over 24 weeks; Duration: 24 weeks
Double-Blind, Placebo-Controlled Trial of Apitegromab on Body Composition During Tirzepatide-Induced Weight Loss
Population: Adults with overweight or obesity; Intervention: Apitegromab + tirzepatide; Comparator: Placebo + tirzepatide; Outcomes: Fat mass loss, visceral fat change, cardiometabolic markers; Duration: 24 weeks; Design: Randomized, double-blind, parallel-group
Prospective Cohort Study of Apitegromab Use During Tirzepatide Therapy and Changes in Body Composition
Population: Adults with overweight or obesity prescribed tirzepatide; Exposure: Use of apitegromab; Comparator: Non-users of apitegromab; Outcomes: Fat mass, visceral fat, cardiometabolic markers measured at baseline and 24 weeks; Duration: 24 weeks
Cross-Sectional Analysis of Body Composition and Cardiometabolic Markers in Adults Receiving Tirzepatide with or without Apitegromab
Population: Adults with overweight or obesity on tirzepatide; Exposure: Current use of apitegromab; Outcomes: Fat mass, visceral fat, cardiometabolic markers measured at a single time point; Duration: Single time point
In Vitro Analysis of Apitegromab Effects on Adipocyte and Myocyte Metabolism in the Presence of Tirzepatide
Population: Human adipocytes and myocytes in culture; Intervention: Apitegromab and tirzepatide exposure; Comparator: Vehicle control; Outcomes: Lipolysis, glucose uptake, gene expression related to fat and muscle metabolism; Duration: 48–72 hours